Next Article in Journal
The Effects of Group and Home-Based Exercise Programs in Elderly with Sarcopenia: A Randomized Controlled Trial
Previous Article in Journal
Map1lc3b and Sqstm1 Modulated Autophagy for Tumorigenesis and Prognosis in Certain Subsites of Oral Squamous Cell Carcinoma
Open AccessArticle

Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series

1
Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Nagano 390-8621, Japan
2
Center for Medical Genetics, Shinshu University Hospital, Matsumoto, Nagano 390-8621, Japan
3
Division of Medical Genetics, Nagano Children’s Hospital, Azumino, Nagano 399-8288, Japan
4
Department of Pediatrics, Keio University School of Medicine, Tokyo 160-8582, Japan
5
Department of Medical Genetics, Shinshu University School of Medicine, Matsumoto, Nagano 390-8621, Japan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(12), 479; https://doi.org/10.3390/jcm7120479
Received: 21 October 2018 / Revised: 15 November 2018 / Accepted: 21 November 2018 / Published: 24 November 2018
(This article belongs to the Section Endocrinology & Metabolism)
Osteogenesis imperfecta (OI) is a connective tissue disorder that is characterized by low bone density leading to recurrent fractures. The efficacy of the anti-resorption drug denosumab for OI with osteoporosis is still largely unknown. We herein describe the clinical outcomes of eight osteoporotic cases of OI to examine the effects and safety of denosumab. This retrospective, consecutive case series included eight patients respectively aged 42, 40, 14, 22, 3, 51, 37, and 9 years. We measured the bone mineral density (BMD) of the lumbar 1–4 spine (L-BMD) and bilateral hips (H-BMD), bone-specific alkaline phosphatase, urinary type I collagen amino-terminal telopeptide, and tartrate-resistant acid phosphatase 5b before and during denosumab therapy. Despite multiple pretreatment fractures in the cohort, no fractures or severe side effects, such as hypocalcemia, were observed during the observational period apart from a fracture in a young pediatric girl. Both L-BMD and H-BMD were increased by denosumab in seven of eight cases. Bone turnover markers were inhibited in most cases by denosumab therapy. Denosumab treatment could generally raise BMD without any adverse effects. The agent therefore represents a good therapeutic option for OI with osteoporosis. View Full-Text
Keywords: bone mineral density; denosumab; fractures; osteogenesis imperfecta; osteoporosis bone mineral density; denosumab; fractures; osteogenesis imperfecta; osteoporosis
Show Figures

Figure 1

MDPI and ACS Style

Kobayashi, T.; Nakamura, Y.; Suzuki, T.; Yamaguchi, T.; Takeda, R.; Takagi, M.; Hasegawa, T.; Kosho, T.; Kato, H. Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series. J. Clin. Med. 2018, 7, 479.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop